Nightingale Health, a Finnish company specializing in health risk detection and preventative health, has received regulatory approval from Singapore’s Health Sciences Authority (HSA) for its blood analysis technology. This approval covers the analysis of eight common clinically used biomarkers: total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, apolipoprotein A1, apolipoprotein B, glucose, and creatinine. With this regulatory clearance, Nightingale Health can introduce its blood testing services in Singapore, offering advanced diagnostic capabilities to healthcare providers and patients in the country.
In November 2023, Nightingale Health announced a collaboration agreement with Innoquest Diagnostics, a clinical diagnostics service provider in Singapore. This partnership aims to enable access to Nightingale Health’s innovative blood analysis technology across Southeast Asia. The regulatory approval from HSA validates the safety, quality, and efficacy of Nightingale Health’s product, positioning the company to meet the healthcare needs of Singaporeans and contribute to the development of more preventative and sustainable health systems in the region.
(Source: Nightingale Health)
